Patent · US Active

TMPRSS6 iRNA compositions and methods of use thereof

US10829763B2 · kind B2 · utility

2Cited by

2References

17Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

James Butler · Lynnfield, US
Martin Maier · Cambridge, US
Kevin Fitzgerald · Brookline, US
Shannon Fishman · Cambridge, US
Donald C. Foster · Lake Forest Park, US
Vasant Jadhav · Cambridge, US
Stuart Milstein · Cambridge, US

Key dates

Filing date	Feb 7, 2019
Grant date	Nov 10, 2020
Priority date	—
Expiry date	Feb 7, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.